Mefenorex (Rondimen).
Mefenorex, N-(3-chloropropyl)-alpha-methylphenethylamine, (RONDIMEN), is included in the list of centrally acting stimulants and/or hallucinogens or related compounds to be considered by a World Health Organization (WHO) Expert Committee in 1985 for possible scheduling under the Convention on Psychotropic Substances, 1971. The therapeutic efficacy of mefenorex as an adjunctive support in the treatment of obesity for limited periods of time, as well as its ability to be well tolerated, has been amply demonstrated. There have been no reports of actual abuse. There have been no reports of illicit trafficking, falsification of packages or materials, or clandestine laboratories manufacturing the compound. Data from preclinical and clinical studies do not suggest a potential for abuse similar to that of amphetamine or related compounds. Moreover, the lack of pulmonary hypertension with mefenorex has been demonstrated in both preclinical and clinical studies. There have been no reports of any public health or social problems associated with mefenorex use. The compound is a well-tolerated anorectic agent with little central stimulant activity.
D000328:Adult; D000662:Amphetamines / Q000009:adverse effects / Q000494:pharmacology; D001067:Appetite Depressants; D002493:Central Nervous System Diseases / Q000139:chemically induced; D055598:Chemical Phenomena; D002621:Chemistry; D004361:Drug Tolerance; D005260:Female; D006801:Humans; D009765:Obesity / Q000188:drug therapy; D019966:Substance-Related Disorders
D000662:Amphetamines; D001067:Appetite Depressants; C000450:mefenorex